Phase III ADAURA study showed adjuvant osimertinib improves DFS (HR 0.17) in respected stage II-III NCSLC, no OS data yet 
CTONG 1104 showed no OS benefit with 2 years adjuvant gefitinib vs chemo in node positive resected NSCLC
Phase III SINDAS showed PFS & OS benefit in adding SBRT to EGFR TKI in oligometastatic disease
poziotinib, osimertinib 160mg & amivantamab have activities in EGFR exon 20 mutations, more data is needed
DESTINY Lung-01 showed promising activities with the use of T-DXd, an ADC targeting HER2 with chemo-load in HER2 positive (mutation & amplification) NSCLC, toxicity an issue, dose needs refining
Phase III ALEX study updated OS results showed better 5-year survival rate (62.5% vs 45.5%) & median OS (not reached vs 57.4 months) with alecrinib compared to crizotinib
Phase II GEOMETRY mono-1 study showed promising activity of capmatinib in MET amplification NSCLC
Phase I Sym015 showed promising activity in the use of MET antibody mixture in both MET amplified & MET exon 14 skipping mutation NSCLC
Registration data for Phase I/II ARROW study for the use of praseltinib (BLU667) in RET-fusion positive NSCLC showed durable response with 96% tumour reduction in first line setting
Phase II ECOG-ACRIN EA5161 study showed addition of nivolumab to chemotherapy improved PFS and OS in first line extensive stage small cell lung cancer adding to body of evidence on the use of IO-chemo combination in this setting
Phase III Keynote 604 is ‘negative positive trial’ with addition of pembrolizumab to chemotherapy in extensive stage small cell lung cancer improved PFS & OS but did not cross superiority threshold for improvement in survival
Updated results of Phase III CASPIAN study showed ongoing OS benefit with addition of durvalumab to chemo in 1L Rx of ES SCLC regardless of presence of brain metastases, no benefit in the addition of tremelimumab
Phase II PrE0505 study showed promising activity with addition of durvalumab to chemotherapy in unresectable malignant mesothelioma #MPM Phase III trial data is needed
Phase II RAMES study showed the addition of ramucirumab to gemcitabine as 2L Rx for malignant mesothelioma #MPM improved both PFS and OS
Phase II CITYSCAPE study showed addition of tiragolumab (anti-TIGIT mAb) to atezolizumab improved PFS especially in PDL1 >50% sub-group (HR 0.3) as 1L Rx of NSCLC
Updated phase III Checkmate 227 results showed ongoing OS benefit of ipilimumab/nivolumab combination over chemotherapy irrespective of PDL1 status as 1L Rx of metastatic NSCLC, median DOR (months) improved with ipi/nivo vs chemo 23.2 v 5.7 (PDL1>1%) and 18.0 v 4.8 (PDL1<1%)
Phase III Checkmate 9LA showed addition of ipilimumab and nivolumab to chemotherapy confers PFS and OS benefits across histologies and PDL1 status as 1L Rx of advanced NSCLC
the Phase II VISION trial showed promising activity with the use of tepotinib in the Rx of metastatic NSCLC with MET exon 14 skipping mutation, 2 posters being presented at #ASCO20 and a @NEJM paper is out now nejm.org/doi/full/10.10…
these are the posters pertaining to VISION trial
updated results for Phase III NEJ026 study showed that the addition of bevacizumab to erlotinib did not translate to any PFS or OS benefit as 1L Rx in advanced NSCLC harbouring EGFR mutations
*resected
*alectinib
Phase I/II assessing combination of osimertinib & gefitinib as 1L Rx of advanced NSCLC harbouring EGFR mutation (n=27) showed expected great anti-tumour activity (RR 88.9%) and is tolerable (30% gefitinib discontinuation dueto tox & 11% G3 diarrhoea)
